Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Medline Inc. (MDLN) SEC Filings & Earnings Calls

EquiReason read 12 Medline Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-10-21 — Medline initiated voluntary field action removing all Medline Brand beds from market; net sales of affected products ~$60M; estimated costs up to $220M; expects no material impact .

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

MDLNMedline Inc.Follow MDLN — free
Medical Instruments & Supplies · Healthcare
—
Price chart with a free account
Market cap
44.8B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
4 Nov, in 11 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

21 Oct 20268-K · 7.01Medline initiated voluntary field action removing all Medline Brand beds from market; net sales of affected products ~$60M; estimated costs up to $220M; expects no material impact on FY2026 guidance.open

Figures in the filing · each found in the filing text

Net sales of affected products · Medline Brand · FY2026$60M
Estimated costs associated with field action · 2026-2027$220M

Guidance

Company currently does not expect this action to have a material impact on its financial results for fiscal year 2026, including its full year 2026 guidance provided on August 5, 2026.

Risks flagged

Product recall and market exit of Medline Brand beds could lead to significant costs up to $220M, inventory impairment, and customer credits, though management expects no material impact on FY2026 guidance.

“voluntary field action involving the removal, discontinuation, and market exit of all Medline Brand beds ... estimated costs of up to $220 million”
Read the original on SEC EDGAR ↗
15 Oct 20268-K · 5.02Director Joseph P. Baratta resigns from Medline board effective Dec 31, 2026, coinciding with departure from Blackstone; no disagreement with company.open

Risks flagged

Loss of board member with private equity perspective, but no disagreement or operational impact cited

“Mr. Baratta's decision coincides with his previously announced departure from Blackstone Inc. and is not the result of any disagreement with the Company related to the Company's operations, policies, or practices.” · word for word
Read the original on SEC EDGAR ↗
5 Aug 20268-K · 2.02Net sales $7.70B (+12% y/y); net income $139M (-58% y/y); organic sales growth 11.5; Guidance: Organic sales guidance raised to 9-10% (from 8.5-9.5%); Adj EBITDA guidance cut to $3.3-3.4B (from $3.5-3.6B)earningsopen

Figures in the filing · each found in the filing text

net_sales · Q2-2026$7.70B+12% y/y
net_income · Q2-2026$139M-58% y/y
organic_sales_growth · Q2-202611.5%
free_cash_flow · H1-2026$920M
capital_expenditures · H1-2026$207M

Guidance

Organic sales guidance raised to 9-10% (from 8.5-9.5%); Adj EBITDA guidance cut to $3.3-3.4B (from $3.5-3.6B)

Raised organic sales guidance due to strong demand; cut EBITDA guidance due to inflation, investments, and retail softness.

Risks flagged

Fire at Tracy distribution center caused $336M loss before insurance; quality remediation costs; retail channel softness; Middle East conflict inflationary pressure.

“Losses of $336 million related to the fire; quality remediation efforts; retail channel softness; higher than expected inflationary pressure from the Middle East conflict.” · word for word
Read the original on SEC EDGAR ↗
5 Aug 202610-QMedline reported Q2 2026 results with 11.6% revenue growth but a $336M fire loss at Tracy distribution center, partially offset by strong cash flow and debt refinancingopen

Figures in the filing · each found in the filing text

Net sales · Q2-2026$7.68B+12% y/y
Net sales · H1-2026$15.04B+11% y/y
Gross profit · Q2-2026$2.21B+16% y/y
Operating income · Q2-2026$395M-39% y/y
Net income attributable to Medline Inc. · Q2-2026$60M-82% y/y
Net cash provided by operating activities · H1-2026$1.13B+28% y/y
Cash and cash equivalents · 2026-06-27$2.33B

Risks flagged

Distribution center fire disruption

“On June 11, 2026, a fire destroyed the Company's distribution center in Tracy, California. ... The Company has estimated incurred losses of $336 million” · word for word

Insurance recovery uncertainty

“As of June 27, 2026, discussions with the Company’s insurers are ongoing, and, as such, no insurance recoveries have been recorded.” · word for word
Read the original on SEC EDGAR ↗
9 Jul 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open

Risks flagged

Key executive departure may cause operational disruption.

“COO retirement for health reasons; search for successor launched.”
Read the original on SEC EDGAR ↗
2 Jun 20268-K · 1.01, 2.03, 8.01Selling stockholders completed underwritten public offering of 72,554,594 shares at $37.00 per share; also issued senior secured notes due 2031/2033 and amended credit agreement.open

Risks flagged

Increased leverage from new debt issuance, though proceeds used to repay existing obligations.

“New debt of $4.75B issued, but net leverage impact unclear as proceeds repay existing debt.”
Read the original on SEC EDGAR ↗
6 May 202610-QNet sales $7.35B (+11% y/y); Gross profit $1.84B (+1% y/y); Operating income $422M (-26% y/y)open

Figures in the filing · each found in the filing text

Net sales · Q1-2026$7.35B+11% y/y
Gross profit · Q1-2026$1.84B+1% y/y
Operating income · Q1-2026$422M-26% y/y
Net income · Q1-2026$239M-26% y/y
Cash and cash equivalents · 2026-03-28$2.24B
Inventories, net · 2026-03-28$4.81B

Risks flagged

Margin compression risk

“Operating income $422 (2026) vs $571 (2025), decrease of 26%.”

Leverage risk

“Long-term borrowings $12,495M as of March 28, 2026.”
Read the original on SEC EDGAR ↗
6 May 20268-K · 2.02Net sales $7.40B (+11% y/y); Organic Sales growth 10.1; Net income $239M (-26% y/y); Guidance: Organic Sales guidance raised to 8.5%-9.5% from 8%-9%earningsopen

Figures in the filing · each found in the filing text

Net sales · Q1-2026$7.40B+11% y/y
Organic Sales growth · Q1-202610.1%
Net income · Q1-2026$239M-26% y/y
Adjusted EBITDA · Q1-2026$776M-11% y/y
Diluted earnings per share · Q1-2026$0.16
Adjusted Diluted EPS · Q1-2026$0.33
Net cash provided by operating activities · Q1-2026$412M
Free Cash Flow · Q1-2026$316M

Guidance

Organic Sales guidance raised to 8.5%-9.5% from 8%-9%

Raising Organic Sales guidance reflects strong demand; margin pressure from tariffs and costs; maintaining Adjusted EBITDA outlook.

Risks flagged

Tariff impact on cost of goods sold pressuring margins; net income and Adjusted EBITDA declined despite revenue growth.

“higher costs of goods sold including the impact of tariffs” · word for word

Higher operating expenses to support new customer growth and IPO bonus may persist.

“higher operating expenses to support new customer growth and an employee bonus related to the Company’s IPO” · word for word
Read the original on SEC EDGAR ↗
23 Apr 2026DEF 14AMedline Inc. filed its 2026 proxy statement (DEF 14A) detailing executive compensation, IPO and secondary offering details, and governance matters.open

Figures in the filing · each found in the filing text

Net Sales · FY2025$28.43B+12% y/y
Net Income · FY2025$1.16B-4% y/y
Adjusted EBITDA · FY2025$3.47B+3% y/y
Free Cash Flow · FY2025$1.30B-8% y/y
Organic Sales Growth · FY202510.5%
Net Capital Expenditures · FY2025$447M+26% y/y
Adjusted EBITDA Margin · FY202512.2%
Plan Adjusted EBITDA · FY2025$3.60B
Net Sales (Plan) · FY2025$28.43B
IPO Proceeds · 2025-12-18$5.08B

Risks flagged

Tax Receivable Agreement Liquidity Risk

“Our obligations under the Tax Receivable Agreement could have a substantial negative impact on our liquidity.” · word for word

Concentrated Ownership and Control

“Mozart HoldCo, Inc. beneficially owns 50.0% of Class B common stock, giving the Mills family significant voting power.”

Related Party Transactions

“Andrew J. Mills, a member of our board of directors, received an allocation of term loans under our Senior Secured Credit Facilities, of which $17.8 million and $17.6 million principal remained outstanding as of December 31, 2024 and 2025, respectively.” · word for word
Read the original on SEC EDGAR ↗
25 Feb 202610-KFiling text contains only boilerplate risk factors and legal disclaimers; no operational, financial, or forward-looking signals.SEC ↗
25 Feb 20268-K · 2.02Net sales $7.80B (+15% y/y); Net income $180M (-38% y/y); Adjusted EBITDA $805M (-1% y/y); Guidance: FY2026 organic sales growth 8-9%, adjusted EBITDA $3.5-$3.6Bearningsopen

Figures in the filing · each found in the filing text

Net sales · Q4-2025$7.80B+15% y/y
Net income · Q4-2025$180M-38% y/y
Adjusted EBITDA · Q4-2025$805M-1% y/y
Full year net sales · FY2025$28.40B+12% y/y
Full year net income · FY2025$1.20B-4% y/y
Full year Adjusted EBITDA · FY2025$3.50B+3% y/y
Net cash provided by operating activities · FY2025$1.70B
Free cash flow · FY2025$1.30B
New customer signings · FY2025$2.40B

Guidance

FY2026 organic sales growth 8-9%, adjusted EBITDA $3.5-$3.6B

Strong revenue growth with margin pressure from tariffs; guidance implies continued momentum.

Risks flagged

Tariff impact on cost of goods sold and margins.

“Higher costs of goods sold due to tariffs.” · word for word

IPO-related expenses and higher operating costs pressure profitability.

“Higher operating costs, including investments in headcount and IPO-related expenses.” · word for word
Read the original on SEC EDGAR ↗
22 Dec 20258-K · 1.01, 3.03, 5.02, 5.03, 8.01IPO shares issued 248,439,654; IPO price per share $29.00; Debt repayment - Euro Term Loan $731Mopen

Figures in the filing · each found in the filing text

IPO shares issued · Q4-2025248,439,654
IPO price per share · Q4-2025$29.00
Debt repayment - Euro Term Loan · Q4-2025$731M
Debt repayment - 2028 Term Loan · Q4-2025$3.29B

Risks flagged

Post-IPO governance complexity with multiple director nomination agreements

“Director Nomination Agreements with Blackstone, Carlyle, Hellman & Friedman, Mills Family”
Read the original on SEC EDGAR ↗

Government contract awards

federal awards · contract value, often multi-year
DateAgencyValueWhat for
2026-09-22Department of Veterans Affairs$82MEXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF AUG 2026
2026-09-08Office of Assistant Secretary for Prepar$7MBPA CALL ORDER FOR RESP IV ADULT
2026-08-20Department of Veterans Affairs$87MEXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF JULY 2026
2026-08-05Indian Health Service$9MMEDLINE FEDERAL BLUE. FUNDING FOR PURCHASE MEDICAL AND SURGICAL SUPPLIES FOR FEDERAL CUSTOMERS
2026-07-20Department of Veterans Affairs$81MEXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF JUNE 2026
2026-06-26Department of Veterans Affairs$84MEXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF MAY 2026
2026-05-26Department of Veterans Affairs$82MEXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF APRIL 2026
2026-04-21Department of Veterans Affairs$78MEXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF MARCH 2026
2026-03-13Department of Veterans Affairs$71MEXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF JANUARY 2026
2026-03-13Department of Veterans Affairs$68MEXPRESS REPORT: MEDICAL SURGICAL PRIME VENDOR EXPENDITURES FOR THE MONTH OF FEBRUARY 2026

Medline Inc. — questions

What did Medline Inc. file recently?
12 SEC filings in the last 12 months. Latest: 8-K on 2026-10-21 — Medline initiated voluntary field action removing all Medline Brand beds from market; net sales of affected products ~$60M; estimated costs up to $220M; expects no material impact on FY2026 guidance.

Every figure on this page comes from Medline Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.